Phenotypes associated with this allele
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation
(1 available);
any
Gt(ROSA)26Sor mutation
(942 available)
Hdac1tm1.1Mrl mutation
(0 available);
any
Hdac1 mutation
(36 available)
Hdac2tm1.1Rdp mutation
(1 available);
any
Hdac2 mutation
(38 available)
|
|
|
cellular
|
• tamoxifen-treated mouse embryonic fibroblasts exhibit a 2-fold reduction in S-phase cells and an increase in G1 phase cell compared with control cells
|
|
• tamoxifen-treated mouse embryonic fibroblasts exhibit growth arrest compared with control cells
|
|
• in tamoxifen-treated mouse embryonic fibroblasts
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hdac1tm1.1Mrl mutation
(0 available);
any
Hdac1 mutation
(36 available)
Hdac2tm1.1Rdp mutation
(1 available);
any
Hdac2 mutation
(38 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
|
|
|
hematopoietic system
|
• megakaryocytes from pIpC-treated mice exhibit aberrant nuclear morphology and mitotic figures and are frequently found intra-vascular or extravasating into bone marrow blood vessels and in the liver compared with control cells
|
|
• in the bone marrow of pIpC-treated mice without increased apoptosis
|
|
• 2-fold in pIpC-treated mice
|
|
• 6-fold in pIpC-treated mice
|
behavior/neurological
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hdac1tm1.1Mrl mutation
(0 available);
any
Hdac1 mutation
(36 available)
Hdac2tm1.1Rdp mutation
(1 available);
any
Hdac2 mutation
(38 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
|
|
|
mortality/aging
|
• mice are moribund 9 days after pIpC treatment
|
hematopoietic system
|
• 20-fold in the bone marrow of pIpC-treated mice with increased apoptosis
|
|
• 5-fold in pIpC-treated mice
|
|
• 16-fold in pIpC-treated mice
|
cellular
|
• apoptotic megakaryocytes in pIpC-treated mice
|
behavior/neurological
cardiovascular system